Clinical trial for BI 3034701 is expected to evaluate the safety, tolerability, and pharmacokinetics in healthy men and overweight or obese individuals aged 18-55 years old.
Reportedly, data from the Vivacity-MG3 trial marks the first time an FcRn blocker demonstrated superiority over placebo in treated generalized myasthenia gravis (gMG).
A three-part framework for a more comprehensive conceptual model of patient experience data can provide a more rounded understanding of patient experiences in clinical trials and beyond.
Improved diversity in clinical trials can be achieved by exploring opportunities for research in developing countries that have not historically participated in large-scale, industry-sponsored clinical trials.